Patent ID: 6586438
Filing Date: 2003-07-01
Classification: A61K,A61P,Y10S

Abstract:
A method for first line treatment of type 2 diabetes in a drug naive human patient, which comprises administering a drug to a drug naÃ¯ve human patient in need of treatment, as first line therapy, a therapeutically effective low dose of a pharmaceutical formulation comprising a low dose combination of metformin and at least one or more other antidiabetic agent, which is one or more of a glucosidase inhibitor, a glucagon-like peptide-1 (GLP-1), insulin, a PPAR &agr;/&ggr; dual agonist other than a thiazolidinedione, a meglitimide and an aP2 inhibitor, which provides at least substantially equivalent efficacy in treating diabetes in drug naive patients, but with substantially reduced side effects, as compared to metformin and said other antidiabetic agent employed in substantially higher daily dosages, wherein the dose of metformin is in an amount to provide a daily dosage within the range from about 160 mg to about 750 mg.